NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade

In conclusion, NDRG2 serves as an inhibitor of SCLC, and its cancer-inhibiting effects are achieved through the suppression of AKT/mTOR via the activation of PTEN. This work suggests that NDRG2 is a potential druggable target for SCLC treatment.PMID:38537875 | DOI:10.1016/j.taap.2024.116915

Source: Toxicology and Applied Pharmacology - March 27, 2024 Category: Toxicology Authors: Zhenchuan Ma Yuefeng Ma Jie Feng Zhengshui Xu Chuantao Cheng Jie Qin Shaomin Li Jiantao Jiang Ranran Kong Source Type: research